Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company pioneering arenavirus-based immunotherapies for cancer and infectious diseases. This page aggregates official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships, providing investors and researchers a centralized resource for tracking the company’s progress.
Users will find timely updates on HOOKIPA’s Vaxwave® and Therat® platforms, which leverage viral vector technology to stimulate durable immune responses. Key content includes trial results for HPV16+ head and neck cancer therapies, hepatitis B/HIV collaboration updates, and financial disclosures. The platform’s stakeholders to monitor developments in immunotherapy approaches designed to overcome traditional treatment limitations.
Bookmark this page for direct access to press releases, SEC filings, and event transcripts. Check regularly for updates on HOOKIPA’s pipeline advancements and industry collaborations that shape its position in the immuno-oncology landscape.
HOOKIPA Pharma has announced its decision not to proceed with the previously discussed all-share acquisition of Poolbeg Pharma plc. This decision follows the non-binding discussions announced on January 2, 2025, and a subsequent PUSU extension on January 30, 2025.
The company retains the right to revisit this decision under specific circumstances, including: with Poolbeg's board agreement, following a third-party offer for Poolbeg, after a Rule 9 waiver or reverse takeover announcement by Poolbeg, or if the Panel on Takeovers and Mergers determines a material change in circumstances.
Moelis & Company is acting as financial adviser to HOOKIPA in this matter.
HOOKIPA Pharma has announced its decision not to proceed with the previously discussed all-share acquisition of Poolbeg Pharma plc. This decision follows the non-binding discussions announced on January 2, 2025, and a subsequent PUSU extension on January 30, 2025.
The company reserves the right to revisit this decision under specific circumstances, including: agreement from Poolbeg's board, announcement of a third-party offer for Poolbeg, announcement of a Rule 9 waiver or reverse takeover by Poolbeg, or if the Panel on Takeovers and Mergers determines a material change in circumstances.
Moelis & Company is acting as financial adviser to HOOKIPA in this matter. The announcement will be available on HOOKIPA's website by noon the following business day.
HOOKIPA Pharma (NASDAQ: HOOK) has completed enrollment for its Phase 1b clinical trial of HB-500, a next-generation therapeutic HIV vaccine developed in collaboration with Gilead Sciences. The trial, which enrolled 30 participants across five U.S. sites, began on July 1, 2024, with primary completion expected in H2 2025.
The Phase 1b trial (NCT06430905) aims to evaluate safety, tolerability, reactogenicity, and immunogenicity of repeated HB-500 doses in HIV patients on suppressive antiretroviral treatment. The study design includes two dose escalation cohorts with participants randomized to receive either HB-500 or placebo.
HB-500 is designed to induce robust and durable immunity as part of a combination strategy for potential functional HIV cure. Under the collaboration agreement, HOOKIPA will advance the program through Phase 1b completion, after which Gilead has exclusive rights to assume further development.
Poolbeg Pharma and HOOKIPA Pharma have provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer is made
2. Participate in the proposed Fundraise for up to $8.7495 million, in line with its existing contractual obligations
The companies emphasize that all discussions regarding the potential combination remain non-binding and non-exclusive, with no guarantee that a firm offer will be made or that any transaction will be completed.
HOOKIPA Pharma Inc (HOOK) has filed a Form 8 Public Opening Position Disclosure on January 8, 2025, related to takeover code regulations. The disclosure reveals detailed information about stock positions and options held by company directors and executives. Key directors Julie O'Neill and David R. Kaufman each hold less than 500 common shares. The company has granted various stock options to directors under its 2019 Stock Option and Incentive Plan, with exercise prices ranging from $6.44 to $166.10 and different vesting schedules. Notable grants include 108,695 restricted stock units to Malte Peters and 69,875 to Terry Coelho, both vesting in two equal installments on July 22, 2025 and 2026.
HOOKIPA Pharma (NASDAQ: HOOK) has issued a notice to shareholders regarding U.K. disclosure requirements related to its potential all-share acquisition of Poolbeg Pharma plc, which was announced on January 2, 2025. The notice specifically addresses Rule 8 of the UK City Code on Takeovers and Mergers.
Under Rule 8.3, shareholders with interests of 1% or more in any class of relevant security must make both an Opening Position Disclosure and a Dealing Disclosure if they trade in any relevant security during the offer period. The company's common stock, Class A common stock, and Series A, A-1, and A-2 convertible preferred stock are considered relevant securities for this offer period.
Poolbeg Pharma and HOOKIPA Pharma have announced important updates regarding their potential combination. Gilead Sciences, a significant HOOKIPA shareholder owning 19.4% (1,875,947 shares) of HOOKIPA's issued share capital, has indicated its intention to vote in line with HOOKIPA Board's recommendation for a formal offer and participate in the proposed fundraise.
HOOKIPA has revised its fundraising plans, now expecting to undertake a 100% primary private placement of approximately $30 million+, an increase from the previously announced 'up to $30 million'. Oppenheimer & Co. Inc. has been engaged as the placement agent for this private placement fundraise.
The companies emphasize that all discussions about the potential combination remain non-binding and non-exclusive, with no guarantee that a firm offer will be made or any transaction completed.
HOOKIPA Pharma has issued an amendment to its Rule 2.4 announcement from January 2, 2025, regarding a potential combination with Poolbeg Pharma plc. The amendment corrects the ISIN of HOOKIPA's common stock from US43906K1007 to US43906K2096, which became effective after the company's 1-for-10 reverse stock split on July 9, 2024.
The company confirms having 9,655,022 shares of common stock, 2,399,517 shares of Class A common stock, 370 shares of Series A convertible preferred stock, 10,800 shares of Series A-1 convertible preferred stock, and 15,268 shares of Series A-2 convertible preferred stock outstanding. Class A common stock holders can convert ten shares into one common stock share, while Series A, A-1, and A-2 preferred stock can be converted into 100 common shares each, subject to ownership limitations.
HOOKIPA Pharma Inc. (HOOK) and Poolbeg Pharma plc have entered into non-binding discussions for an all-share acquisition. The proposed combination would create a Nasdaq-listed clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and other serious diseases.
Key terms include:
- Poolbeg shareholders to receive 0.03 HOOKIPA shares for each Poolbeg share
- Poolbeg shareholders expected to own ~55% and HOOKIPA shareholders ~45% of combined entity
- HOOKIPA plans $30M private placement fundraise
- Combined group to maintain Nasdaq listing while Poolbeg delists from AIM
The deal aims to create a diversified clinical pipeline led by multi-KRAS targeting HB-700 and Phase 2-ready POLB 001, with expected clinical data across multiple programs over next 24 months. The combined entity would also maintain two partnered programs with Gilead Sciences.
HOOKIPA Pharma (NASDAQ: HOOK) reported Q3 2024 financial results and business updates. Key highlights include completion of Phase 2 study enrollment for eseba-vec + pembrolizumab in HPV+ HNSCC with 68 patients, and first patients dosed in Phase 2 adjuvant therapy study with MSKCC. The company reported Q3 revenue of $4.7 million, down from $6.9 million in Q3 2023. Net loss was $13.8 million compared to $19.1 million in the same period last year. Cash position stood at $60.0 million as of September 30, 2024. The company received a $5.0 million milestone payment from Gilead for HB-500 HIV-1 treatment trial initiation.
